Company intelligence / Profile preview
Ostentus Therapeutics
Newport Beach, California, United Statesostentustherapeutics.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Preclinical
01
Overview
OST-01 has demonstrated anti-cancer activity in leukemia, glioblastoma, lung, colorectal, triple negative breast, ovarian, and pancreatic cancers both in vitro and in vivo. The compound targets both leukemic and cancer stem cells by suppressing upregulated "stemness" signaling. Safety has been demonstrated by the lack of toxic and adverse health effects on both normal and cancer mouse models[2][3].
- Therapeutic areas
- Oncology
- Modalities
- Natural compoundsplant-derived compoundsphytochemicals
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
City of Hope
Beyond the preview
Go deeper on Ostentus Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ostentus Therapeutics.